Decentralised, point-of-care CAR-T for multiple myeloma
Mené en Espagne sur 35 patients atteints d'un myélome multiple réfactaire ou récidivant (âge médian : 61 ans ; durée médiane de suivi : 12,1 mois), cet essai multicentrique évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité de ARI0002h, une immunothérapie à base de lymphocytes CAR-T ciblant BCMA, administrée de façon fractionnée puis en dose "booster"
BCMA chimeric antigen receptor (CAR) T-cell therapy represents a major breakthrough in the treatment of multiple myeloma. 1
Idecabtagene vicleucel and ciltacabtagene autoleucel are so far the only two industrial BCMA CAR T-cell therapies that have received regulatory approval. Both have shown unprecedented clinical efficacy, translating into progression-free survival that largely exceeds the expected 3–4-month progression-free survival in relapsed or refractory multiple myeloma. In The Lancet Oncology, Aina Oliver-Caldés and colleagues report the results of ARI0002h, a BCMA CAR T-cell therapy developed in Spain by an academic group, in 30 patients with relapsed or refractory multiple myeloma. Similar to an Israeli initiative, this study confirms that in-house production of CAR T cells in an academic setting and according to good manufacturing practice standards is feasible, resulting in high-quality products with potent activity. All 30 patients responded, and a complete response or better was observed in 20 (67%) patients after a median follow-up of 18 months (IQR 15–20). The median progression-free survival was 14·5 months (95% CI 12·8–not reached).
The Lancet Oncology , commentaire, 2022